Navigation Links
Omeros to Present at the 12th Annual Needham Healthcare Conference
Date:4/24/2013

SEATTLE, April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12th Annual Needham Healthcare Conference next week.  Gregory A. Demopulos , M.D., chairman and chief executive officer, is scheduled to present at 8:40 a.m. Eastern Time on Wednesday, May 1, 2013.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
2. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
5. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
6. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
9. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
10. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
11. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation ... (OICR) are pleased to report that Fusion Pharmaceuticals Inc. ... Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as ... HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain ... to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting ... in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed ...
(Date:2/23/2017)... , Feb. 23, 2017  Capricor Therapeutics, Inc. (NASDAQ: ... other medical conditions, today announced that Linda Marbán, Ph.D, president ... upcoming investor conferences: Cowen and Company ... 10:00 am ET Boston, MA ... at 9:00 am PT (12:00 pm ET) Dana ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... Kendall Research Systems, LLC (KRS) clinical development program. KRS is a ... technology for research and clinical applications. The terms of the transaction were not ...
Breaking Biology Technology:
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)...  Aware, Inc. (NASDAQ: AWRE ), a leading ... for its quarter and year ended December 31, 2016. ... $3.9 million compared to $6.9 million in the same quarter ... was $0.6 million compared to $2.6 million in the fourth ... 2016 was $0.5 million, or $0.02 per diluted share, which ...
Breaking Biology News(10 mins):